Dyne Therapeutics, Inc.

Symbol: DYN

NASDAQ

25.95

USD

Market price today

  • -8.1705

    P/E Ratio

  • -0.0768

    PEG Ratio

  • 2.10B

    MRK Cap

  • 0.00%

    DIV Yield

Dyne Therapeutics, Inc. (DYN) Financial Statements

On the chart you can see the default numbers in dynamics for Dyne Therapeutics, Inc. (DYN). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Dyne Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

balance-sheet.row.cash-and-short-term-investments

0123.1256376.6
345.3
14.6
8.1
397
1906
605
1948
868
361
465
397
549
780
432

balance-sheet.row.short-term-investments

01.583.9175.7
44.5
0
0
32
130
100
78
25
13
69
106
78
87
104

balance-sheet.row.net-receivables

0000
0
0
0
513
386
402
270
420
108
6
230
212
340
426

balance-sheet.row.inventory

0000
0
0
0
445
445
597
208
181
101
57
121
141
184
199

balance-sheet.row.other-current-assets

06.39.65.8
3.8
0.1
0
169
250
341
248
216
473
144
1496
1136
1499
606

balance-sheet.row.total-current-assets

0129.4256382.4
345.3
14.8
8.2
1524
2987
1945
2674
1685
1043
672
2244
2038
2803
1663

balance-sheet.row.property-plant-equipment-net

033.438.441
1.9
1.5
0.1
8884
7121
8347
3255
3315
3022
3334
6273
9071
10869
10689

balance-sheet.row.goodwill

0000
0
0
0
772
799
797
0
0
0
0
0
0
433
438

balance-sheet.row.intangible-assets

0000
0
0
0
25
38
102
27
108
271
0
141
380
437
497

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
797
837
899
27
108
271
0
141
380
870
935

balance-sheet.row.long-term-investments

02.32.32.3
2.3
0
0
26
16
18
2
11
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
571
427
0
20
100
18
5
12
0
0
0

balance-sheet.row.other-non-current-assets

009.60
3.8
0.2
0
-31
1665
330
5254
72
181
116
1343
-536
-329
-66

balance-sheet.row.total-non-current-assets

035.750.343.3
8
1.7
0.1
10247
10066
9594
8558
3606
3492
3455
7769
8915
11410
11558

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0165.1306.3425.7
353.3
16.4
8.3
11771
13053
11539
11232
5291
4535
4127
10013
10953
14213
13221

balance-sheet.row.account-payables

022.95.34
3.4
1.3
0.5
367
332
292
216
329
112
15
134
181
303
292

balance-sheet.row.short-term-debt

04.74.63.9
0
0
0
105
201
83
31
13
29
4
148
807
64
51

balance-sheet.row.tax-payables

0000
0
0
0
64
3
3
4
274
1
0
0
0
0
0

balance-sheet.row.long-term-debt-total

022.725.928.7
0
0
3.4
8328
8778
7206
7075
1979
1386
584
4426
807
64
51

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

023.418.220.8
7.5
1.1
0.2
570
378
408
414
279
111
135
1271
853
1329
611

balance-sheet.row.total-non-current-liabilities

022.725.928.7
0
0
12.4
8481
8953
7418
7312
2257
1738
734
5403
1166
564
439

balance-sheet.row.other-liabilities

0000
0
0
0
340
1142
388
216
103
-53
2122
299
4961
7462
7254

balance-sheet.row.capital-lease-obligations

022.730.532.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

073.85457.5
11
2.4
13.1
9870
11011
8618
8209
3081
2032
3015
7267
7974
9728
8692

balance-sheet.row.preferred-stock

0000
0
27.4
9.1
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0000
0
0
0
1
1
1
1
1
1
1
1
6
5
5

balance-sheet.row.retained-earnings

0-632.5-396.6-228.5
-79.2
-19.7
-4.9
-1851
-1927
-686
-736
-463
-107
-4841
-3196
0
0
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

00-0.6-0.3
0
0
0
32
21
19
20
58
11
-53
-53
-150
-215
-25

balance-sheet.row.other-total-stockholders-equity

0723.8649.5596.9
421.6
6.4
-9
3719
3947
3587
3738
2614
2598
6005
5994
3046
4725
4526

balance-sheet.row.total-stockholders-equity

091.3252.4368.2
342.4
14
-4.9
1901
2042
2921
3023
2210
2503
1112
2746
2902
4515
4506

balance-sheet.row.total-liabilities-and-stockholders-equity

0165.1306.3425.7
353.3
16.4
8.3
11771
13053
11539
11232
5291
4535
4127
10013
10953
14213
13221

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

091.3252.4368.2
342.4
14
-4.9
1901
2042
2921
3023
2210
2503
1112
2746
2902
4515
4506

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

03.883.9175.7
44.5
0
0
58
146
118
80
36
13
69
106
78
87
104

balance-sheet.row.total-debt

027.430.532.6
0
0
3.4
8433
8979
7289
7106
1992
1415
588
4574
1614
128
102

balance-sheet.row.net-debt

0-94.2-141.7-168.2
-300.9
-14.6
-4.7
8068
7203
6784
5236
1149
1067
192
4283
1143
-565
-226

Cash Flow Statement

The financial landscape of Dyne Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

cash-flows.row.net-income

0-235.9-168.1-149.3
-59.4
-14.9
-4.8
76
-1240
50
-67
-356
87
-1645
-234
-1262
174
264

cash-flows.row.depreciation-and-amortization

02.51.71.1
0.7
0.3
0
867
766
614
292
467
26
346
408
359
376
333

cash-flows.row.deferred-income-tax

0-2302.6
0
0
0
610
45
477
1
56
0
632
195
-436
73
215

cash-flows.row.stock-based-compensation

02015.217.5
6.6
0
0
44
31
28
19
15
0
0
0
0
0
-522

cash-flows.row.change-in-working-capital

026.3-5.49.3
5.1
1.4
0.6
-1596
938
-860
1029
268
183
-166
488
-910
437
522

cash-flows.row.account-receivables

0000
0
0
0
-47
42
-64
161
-75
-511
49
16
66
68
-114

cash-flows.row.inventory

0000
0
0
0
110
154
-119
-20
24
1
-3
-16
7
3
-13

cash-flows.row.account-payables

023-1.213.7
8.6
1.7
0.6
46
84
90
-131
71
-3
105
-18
-112
-71
-15

cash-flows.row.other-working-capital

03.3-4.1-4.4
-3.5
-0.3
0
-1705
658
-767
1019
248
696
-317
506
-871
437
142

cash-flows.row.other-non-cash-items

0223-0.7
0.5
1.3
0
584
136
-215
-1336
-275
-340
813
-434
2384
-741
-471

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-0.7-3.1-3.6
-1.2
-1.6
-0.1
-224
-326
-275
0
-98
0
-242
-333
0
0
0

cash-flows.row.acquisitions-net

0000
0
0
0
-3319
0
-6078
0
234
0
0
0
0
0
-128

cash-flows.row.purchases-of-investments

0-44.3-121.2-236.7
-44.5
0
0
0
0
-250
0
0
0
0
-508
0
0
0

cash-flows.row.sales-maturities-of-investments

0128.3211.4102.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

0000
0
0
0
784
-1821
5409
-5148
338
348
-12
307
251
-102
-689

cash-flows.row.net-cash-used-for-investing-activites

083.387.2-137.9
-45.7
-1.6
-0.1
-2759
-2147
-1194
-5148
474
348
-254
-534
251
-102
-817

cash-flows.row.debt-repayment

0000
-10
0
0
-2589
-589
-31
-14
-1917
-328
-1624
-63
0
0
0

cash-flows.row.common-stock-issued

054.336.9157.2
246.4
20
0
0
0
0
719
0
0
3
-6
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
-250
-1870
-843
-348
-396
-291
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
-22
-22
-23
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

020.50.6
144.3
0
12.4
1312
3353
39
6375
2606
348
2396
291
-608
148
433

cash-flows.row.net-cash-used-provided-by-financing-activities

054.337.4157.8
380.7
20
12.4
-1299
2742
-265
5210
-154
-328
379
-69
-608
148
433

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
4.3
0
0
0
0
0
-83
0
0
0
0
0

cash-flows.row.net-change-in-cash

0-50.5-29.1-99.6
288.5
6.5
12.4
-3473
1271
-1365
0
495
-107
105
-180
-222
365
-43

cash-flows.row.cash-at-end-of-period

0121.6174.5203.5
303.2
14.6
8.1
365
1776
505
1870
843
348
396
291
471
693
328

cash-flows.row.cash-at-beginning-of-period

0172.1203.5303.2
14.6
8.1
-4.3
3838
505
1870
1870
348
455
291
471
693
328
371

cash-flows.row.operating-cash-flow

0-188.2-153.6-119.6
-46.5
-11.8
-4.2
585
676
94
-62
175
-44
-20
423
135
319
341

cash-flows.row.capital-expenditure

0-0.7-3.1-3.6
-1.2
-1.6
-0.1
-224
-326
-275
0
-98
0
-242
-333
0
0
0

cash-flows.row.free-cash-flow

0-188.9-156.7-123.2
-47.7
-13.5
-4.3
361
350
-181
-62
77
-44
-262
90
135
319
341

Income Statement Row

Dyne Therapeutics, Inc.'s revenue saw a change of NaN% compared with the previous period. The gross profit of DYN is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

income-statement-row.row.total-revenue

0000
0
0
0
506
1366
842
1466
3
3
1585
2323
2468
3549
3103

income-statement-row.row.cost-of-revenue

02.53.31.1
0.7
0.3
0
2932
2281
2028
1145
1145
268
963
1181
1194
1853
2013

income-statement-row.row.gross-profit

0-2.5-3.3-1.1
-0.7
-0.3
0
-2426
-915
-1186
321
-1142
-265
622
1142
1274
1696
1090

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

002.90
-0.8
-1.3
0
0
0
0
-211
0
-59
0
0
-360
-337
0

income-statement-row.row.operating-expenses

0239.7171150
58.6
13.8
4.8
189
161
128
-308
97
-81
135
163
-519
-494
-203

income-statement-row.row.cost-and-expenses

0242.2171150
58.6
13.8
4.8
3121
2442
2156
837
1242
187
1098
1344
675
1359
1810

income-statement-row.row.interest-income

07.62.90.7
0.1
0.3
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

002.90
0.4
0
0
616
625
546
67
97
0
357
363
415
427
384

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

06.22.90.7
-0.8
-1
0
-126
-649
-491
50
-99
-627
-2041
-224
-521
-463
-338

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

002.90
-0.8
-1.3
0
0
0
0
-211
0
-59
0
0
-360
-337
0

income-statement-row.row.total-operating-expenses

06.22.90.7
-0.8
-1
0
-126
-649
-491
50
-99
-627
-2041
-224
-521
-463
-338

income-statement-row.row.interest-expense

002.90
0.4
0
0
616
625
546
67
97
0
357
363
415
427
384

income-statement-row.row.depreciation-and-amortization

02.51.71.8
0.7
-0.8
0
867
766
614
292
467
26
346
408
359
376
333

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0-242.2-171-150
-58.6
-13.8
-4.8
-412
-640
64
-318
-318
714
-236
-11
-834
709
605

income-statement-row.row.income-before-tax

0-235.9-168.1-149.3
-59.4
-14.9
-4.8
-538
-1289
-427
-268
-417
87
-2277
-235
-1355
246
267

income-statement-row.row.income-tax-expense

00-2.90
-0.7
-1.3
0
-610
-45
-474
117
-58
-627
-632
197
315
-75
-151

income-statement-row.row.net-income

0-235.9-165.2-149.3
-58.7
-13.5
-4.8
76
-1240
50
-67
-356
87
-1645
-234
-1262
174
264

Frequently Asked Question

What is Dyne Therapeutics, Inc. (DYN) total assets?

Dyne Therapeutics, Inc. (DYN) total assets is 165082000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.515.

What is company free cash flow?

The free cash flow is -2.720.

What is enterprise net profit margin?

The net profit margin is -67.951.

What is firm total revenue?

The total revenue is -70.183.

What is Dyne Therapeutics, Inc. (DYN) net profit (net income)?

The net profit (net income) is -235937000.000.

What is firm total debt?

The total debt is 27415000.000.

What is operating expences number?

The operating expences are 239701000.000.

What is company cash figure?

Enretprise cash is 0.000.